Symbiotec Pharmalab Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kguxr6oxntu95bf8vb44cfpp.pdf

Key Takeaways


The Platform Pivot: From API Supplier to Multi-Vertical CDMO

Anil Satwani: "We make their product viable. We take it from their innovation to EBITDA-positive projections in next 18 months. That's our USP... It's not about capex, it's also the opex economics. I don't think Western world is in a good position, relatively speaking."

Complex Injectables: The DCV Partnership Begins to Monetize

Anil Satwani: "It is not fully monetized as yet. There's more to come. We have only partly monetized this opportunity."

Fermentation CDMO: Two Anchor Tenants, Capacity Filling


API Base Business: The Durable Cash Engine

Anil Satwani: "Our customers have qualified us as their primary API source in their own filings. We earned their position, this position through many years of consistent supply and compliance, and needless to say, we intend to keep earning it."

Biologics: Insulin Delayed, Pipeline Expanding


New Initiatives: Early-Stage Optionality

Anil Satwani: "I realized synthetic biology can move the mountains for us, which will essentially allow us to create our proprietary products in the classical fermentation. And that's the desire, that's our long-term goal."

Guidance & Commitments

CommitmentSpecificsTimeline
Fiscal year revenue growthApproximately 20% growth, with a range of 5 percentage points either sideFY27
Fiscal year EBITDA growthAround 25% growth, with a range of 5 percentage points either sideFY27
Second DCV ANDA filingFile second ANDA for DCV productQ4 FY27
European alt protein Phase 0 productionTechnology transfer and qualification batches at 100 KL scale, production start after ~3 months fine-tuningWithin FY27
European alt protein Phase 1 productionSub-million-liter capacities to commence; significant revenues expected in FY28-29FY28-29
US alt protein commercial batchesFirst commercial batches under 10-year take-or-pay contractQ1 FY28
Insulin drug substance sales revenueSales revenues to commence post regulatory approvalsMid-next year (FY27-28)
DCV product commercializationProducts expected to get commercializedNext year (FY27-28)
DCV ANDA approval and FDA inspectionBoth expected in the latter part of calendar year 2027Latter part of CY2027
Vegan Vitamin D3 non-pharma salesNutraceutical and veterinary sales to startEarly next fiscal year (FY27-28)
Next capex announcementAnnouncement on bags, syringes, or testosteroneMaybe a quarter or two
DCV milestone revenue continuityBalance milestone revenue recognized each upcoming quarter; similar intensity year-on-yearNext couple of years

Key Metrics

MetricQ2 FY27
Consolidated revenue₹280 cr, +43% YoY
API business revenue₹227 cr, +16% YoY
Consolidated EBITDA₹94 cr, +88% YoY; adjusted for one-time IPO expenses of ₹3 cr
API EBITDA margin~30%, stable across Q2 and H1
API gross margin>60%, held steady for both Q2 and H1
PAT₹52 cr, +169% YoY
Milestone revenue recognized (complex injectables)₹53 cr, invoiced in Q2; balance expected in subsequent quarters
Capex investment (H1 FY27)₹113 cr
Net debt₹314 cr as of 30 September
FY27 revenue growth guidance~20%, with a range of 5 percentage points either side
FY27 EBITDA growth guidance~25%, with a range of 5 percentage points either side
Fermentation CDMO capacity (Ujjain)400 KL currently; Phase 1 expansion of 750 KL signed with European alt-protein partner
DCV ANDA filings1 filed with FDA in September; second planned for Q4 FY27
US FDA DMFs filed44
European CEPs filed25